RESUMEN
OBJECTIVE: The purpose of this study was to identify and characterize the clinically significant lesions associated with incidental detection of focal uptake of (18)F-FDG in the bowel at PET/CT. MATERIALS AND METHODS: Among 2,250 consecutively registered patients with various nongastrointestinal malignant diseases who underwent FDG PET/CT as part of their care, patients with the incidental finding of focal bowel uptake of FDG were included in the study. All patients underwent an endoscopic or surgical procedure for characterization of the lesions. The location, intensity of uptake, and appearance of the lesions on PET/CT images were recorded and compared with the endoscopic and surgical pathologic results. RESULTS: Twenty-one of 25 foci of intense uptake in the bowel were associated with endoscopic or surgical abnormalities (positive predictive value, 84%). Seven lesions were malignant (two primary, five secondary); 13 were premalignant (nine tubovillous adenoma, four tubular adenoma); and one lesion was benign (hyperplastic polyp). Eleven lesions detected with endoscopy were not FDG avid, and all 11 were smaller than 1 cm in diameter. There was no statistically significant difference in the maximum standardized uptake values of the benign and malignant lesions. CONCLUSION: The incidental finding of focal FDG uptake in the bowel justifies further investigation of these foci and should not be dismissed as physiologic uptake. Premalignant lesions, such as adenoma, are often found, and early treatment may prevent the development of carcinoma.
Asunto(s)
Fluorodesoxiglucosa F18 , Enfermedades Intestinales/diagnóstico , Enfermedades Intestinales/epidemiología , Tomografía de Emisión de Positrones/estadística & datos numéricos , Técnica de Sustracción/estadística & datos numéricos , Tomografía Computarizada por Rayos X/estadística & datos numéricos , Adulto , Anciano , Femenino , Fluorodesoxiglucosa F18/farmacocinética , Humanos , Incidencia , Hallazgos Incidentales , Enfermedades Intestinales/metabolismo , Mucosa Intestinal/metabolismo , Intestinos/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Radiofármacos/farmacocinética , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Estadística como Asunto , Texas , Adulto JovenRESUMEN
PURPOSE: To investigate clinical implications of FDG uptake in the thyroid glands in patients with advanced breast carcinoma by comparing metabolic and morphologic patterns on positron emission tomography (PET)/computed tomography (CT). METHODS: The institutional review board waived the requirement for informed consent. A retrospective analysis was performed in 146 women (mean age 54 years) with advanced breast carcinoma who received systemic treatment. All patients underwent PET-CT before and after treatment. All PET-CT studies were reviewed in consensus by two reviewers. Morphologic changes including volume and mean parenchymal density of the thyroid glands were evaluated. Maximum standardized uptake value (SUVmax) and total lesion glycolysis (TLG) were determined to evaluate metabolic changes. These parameters were compared between patients with chronic thyroiditis who received thyroid hormone replacement therapy and those who did not. RESULTS: Of the 146 patients, 29 (20%) showed bilaterally diffuse uptake in the thyroid glands on the baseline PET-CT scan. The SUVmax showed a linear relationship with volume (r = 0.428, p = 0.021) and the mean parenchymal density (r = -0.385, p = 0.039) of the thyroid glands. In 21 of the 29 patients (72%) with hypothyroidism who received thyroid hormone replacement therapy, the volume, mean parenchymal density, SUVmax, and TLG of the thyroid glands showed no significant changes. In contrast, 8 of the 29 patients (28%) who did not receive thyroid hormone replacement therapy showed marked decreases in SUVmax and TLG. CONCLUSION: Diffuse thyroid uptake on PET-CT represents active inflammation caused by chronic thyroiditis in patients with advanced breast carcinoma. Diffuse thyroid uptake may also address the concern about subclinical hypothyroidism which develops into overt disease during follow-up.
Asunto(s)
Neoplasias de la Mama/complicaciones , Neoplasias de la Mama/patología , Tiroiditis/metabolismo , Tiroiditis/patología , Adulto , Anciano , Anciano de 80 o más Años , Enfermedad Crónica , Femenino , Fluorodesoxiglucosa F18/metabolismo , Humanos , Persona de Mediana Edad , Tomografía de Emisión de Positrones , Estudios Retrospectivos , Glándula Tiroides/diagnóstico por imagen , Glándula Tiroides/metabolismo , Glándula Tiroides/patología , Tiroiditis/complicaciones , Tiroiditis/diagnóstico , Tomografía Computarizada por Rayos XRESUMEN
PURPOSE: To retrospectively compare morphologic and metabolic changes in bone metastases in response to systemic therapy in patients with metastatic breast cancer (MBC) with integrated positron emission tomography (PET)/computed tomography (CT). MATERIALS AND METHODS: The institutional review board waived the requirement for informed consent and approved this HIPAA-compliant study. A retrospective analysis was performed with 102 women (mean age, 55 years) with MBC who received systemic treatment. All patients underwent integrated PET/CT before and after treatment. Two reviewers analyzed the images in consensus. Morphologic changes, including morphologic patterns, and lesion attenuation were evaluated. Standardized uptake value (SUV) and total lesion glycolysis (TLG) were analyzed to evaluate metabolic changes. Uni- and multivariate analyses were performed to identify factors that enabled response duration (RD) to be predicted. RESULTS: At baseline, the morphologic patterns of the target lesions were lytic (n = 33), sclerotic (n = 22), mixed (n = 42), and unclassified (n = 5). Progression of sclerotic change after treatment was identified in 49 patients (48%). After treatment, the mean attenuation of the lesion increased, whereas the mean SUV and TLG decreased. Increases in attenuation correlated significantly with decreases in SUV (r = -0.510, P < .001) and TLG (r = -0.491, P < . 001). Univariate analysis revealed that the increase in attenuation and the decrease in SUV were potential predictors of RD. Multivariate analysis revealed that an increase in the change in SUV was a significant predictor of RD (relative risk, 2.4; P = .003). CONCLUSION: A decrease in SUV after treatment was an independent predictor of RD in patients with MBC who had bone metastases.
Asunto(s)
Neoplasias Óseas/secundario , Neoplasias de la Mama/patología , Tomografía de Emisión de Positrones , Tomografía Computarizada por Rayos X , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias Óseas/diagnóstico por imagen , Neoplasias Óseas/tratamiento farmacológico , Carcinoma Ductal de Mama/secundario , Carcinoma Lobular/secundario , Progresión de la Enfermedad , Femenino , Fluorodesoxiglucosa F18 , Humanos , Procesamiento de Imagen Asistido por Computador , Persona de Mediana Edad , RadiofármacosRESUMEN
OBJECTIVE: Although 18F-FDG PET/CT is now well established as an accurate method for the staging and restaging of various cancers, it is also well recognized that many false-positive results can occur. One such false-positive is activity within the superior extent of the thymus in the superior mediastinum. CONCLUSION: We reviewed all PET/CT examinations performed in children and young adults under the age of 20 years at our institution over a 2-month period. In 11 (12%) of the 93 examinations, activity was identified in the superior mediastinum of similar intensity to the thymus, which is consistent with activity within the superior thymic extension. In light of the increasing clinical use of FDG PET/CT for cancer imaging, it is important that nuclear medicine physicians and radiologists be aware of this phenomenon to avoid misdiagnosis or overstaging of disease.
Asunto(s)
Fluorodesoxiglucosa F18 , Tomografía de Emisión de Positrones/métodos , Timo/diagnóstico por imagen , Neoplasias del Timo/diagnóstico , Tomografía Computarizada por Rayos X/métodos , Adolescente , Adulto , Niño , Preescolar , Reacciones Falso Positivas , Femenino , Humanos , Aumento de la Imagen/métodos , Lactante , Recién Nacido , Masculino , Mediastino/diagnóstico por imagen , Radiofármacos , Reproducibilidad de los Resultados , Estudios Retrospectivos , Sensibilidad y Especificidad , Técnica de SustracciónRESUMEN
PURPOSE: (18)Fluorodeoxyglucose positron emission tomography (FDG PET) is widely used for the staging of lymphoma. We investigated whether the intensity of tumor FDG uptake could differentiate between indolent and aggressive disease. MATERIALS AND METHODS: PET studies of 97 patients with non-Hodgkin's lymphoma who were untreated or had relapsed and/or persistent disease and had not received treatment within the last 6 months were analyzed, and the highest standardized uptake value (SUV) per study was recorded. Correlations were made with histopathology. RESULTS: FDG uptake was lower in indolent than in aggressive lymphoma for patients with new (SUV, 7.0 +/- 3.1 v 19.6 +/- 9.3; P < .01) and relapsed (SUV, 6.3 +/- 2.7 v 18.1 +/- 10.9; P = .04) disease. Despite overlap between indolent and aggressive disease in the low SUV range (indolent, 2.3 to 13.0; aggressive, 3.2 to 43.0), all cases of indolent lymphoma had an SUV
Asunto(s)
Fluorodesoxiglucosa F18 , Linfoma no Hodgkin/diagnóstico por imagen , Tomografía de Emisión de Positrones , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Fluorodesoxiglucosa F18/farmacocinética , Humanos , Linfoma no Hodgkin/patología , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias/métodos , Radiofármacos/farmacocinéticaRESUMEN
UNLABELLED: Hürthle cell carcinoma is an uncommon and occasionally aggressive differentiated thyroid cancer associated with increased mortality compared with other differentiated thyroid malignancies. Because it generally has lower iodine avidity, 18F-FDG PET has been suggested as a more accurate imaging modality. However, there is limited information with regard to the true diagnostic accuracy and prognostic value of 18F-FDG PET in this disease. METHODS: All patients with Hürthle cell thyroid cancer who underwent their first 18F-FDG PET scan between May 1996 and February 2003 were identified retrospectively. 18F-FDG PET scans were reviewed and compared with all available imaging studies, including CT, ultrasound, and radioiodine scintigraphy (RIS). Abnormal 18F-FDG uptake was assessed visually and by measuring the maximum standardized uptake value (SUVmax) of the most intense lesion. Clinical follow-up for at least 1 y or until death was required for inclusion. RESULTS: Forty-four patients met inclusion criteria. The median follow-up was 2.9 y. There were 24 positive and 20 negative 18F-FDG PET scans with 1 false-positive and 1 false-negative study, resulting in a diagnostic sensitivity of 95.8% and a specificity of 95%. In 5 of 11 patients who had both positive CT and 18F-FDG PET findings, 18F-FDG PET revealed additional sites of disease. Furthermore, 18F-FDG PET correctly classified as negative 3 patients with false-positive CT findings. In 3 of 6 patients with positive RIS, 18F-FDG PET revealed additional sites of metastatic disease. Ten patients with positive 18F-FDG PET had negative RIS. Only 1 patient with negative 18F-FDG PET had positive RIS. The SUVmax also provided prognostic information: In a stepwise fashion, each increase in intensity by SUVmax unit was associated with a 6% increase in mortality (P < 0.001). The 5-y overall survival in patients with SUVmax < 10 was 92%; it declined to 64% in those with SUVmax > 10 (P < 0.01). CONCLUSION: 18F-FDG PET has excellent diagnostic accuracy in Hürthle cell thyroid cancer patients, improving on CT and RIS. Intense 18F-FDG uptake in lesions is an indicator of a poor prognosis. Our data suggest that all patients with Hürthle cell thyroid cancer should undergo 18F-FDG PET as part of their initial postoperative staging and periodically to screen for occult recurrence, particularly in patients with elevated serum thyroglobulin.
Asunto(s)
Adenoma Oxifílico/diagnóstico por imagen , Adenoma Oxifílico/diagnóstico , Fluorodesoxiglucosa F18 , Tomografía de Emisión de Positrones/métodos , Neoplasias de la Tiroides/diagnóstico por imagen , Neoplasias de la Tiroides/diagnóstico , Adenoma Oxifílico/patología , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Pronóstico , Tiroglobulina/sangre , Neoplasias de la Tiroides/patología , Tomografía Computarizada por Rayos X/métodosRESUMEN
UNLABELLED: (18)F-FDG PET has a high accuracy in staging head and neck cancer, but its role in patients with clinically and radiographically negative necks (N0) is less clear. In particular, the value of combined PET/CT has not been determined in this group of patients. METHODS: In a prospective study, 31 patients with oral cancer and no evidence of lymph node metastases by clinical examination or CT/MRI underwent (18)F-FDG PET/CT before elective neck dissection. PET/CT findings were recorded by neck side (left or right) and lymph node level. PET/CT findings were compared with histopathology of dissected nodes, which was the standard of reference. RESULTS: Elective neck dissections (26 unilateral, 5 bilateral; a total of 36 neck sides), involving 142 nodal levels, were performed. Only 13 of 765 dissected lymph nodes harbored metastases. Histopathology revealed nodal metastases in 9 of 36 neck sides and 9 of 142 nodal levels. PET was TP in 6 nodal levels (6 neck sides), false-negative in 3 levels (3 neck sides), true-negative in 127 levels (23 neck sides), and false-positive in 6 levels (4 neck sides). The 3 false-negative findings occurred in metastases smaller than 3 mm or because of inability to distinguish between primary tumor and adjacent metastasis. TP and false-positive nodes exhibited similar standardized uptakes (4.8 +/- 1.1 vs. 4.2 +/- 1.0; P = not significant). Sensitivity and specificity were 67% and 85% on the basis of neck sides and 67% and 95% on the basis of number of nodal levels, respectively. If a decision regarding the need for neck dissection had been based solely on PET/CT, 3 false-negative necks would have been undertreated, and 4 false-positive necks would have been overtreated. CONCLUSION: (18)F-FDG PET/CT can identify lymph node metastases in a segment of patients with oral cancer and N0 neck. A negative test can exclude metastatic deposits with high specificity. Despite reasonably high overall accuracy, however, the clinical application of PET/CT in the N0 neck may be limited by the combination of limited sensitivity for small metastatic deposits and a relatively high number of false-positive findings. The surgical management of the N0 neck should therefore not be based on PET/CT findings alone.
Asunto(s)
Fluorodesoxiglucosa F18/química , Neoplasias de la Boca/diagnóstico , Neoplasias de la Boca/radioterapia , Tomografía de Emisión de Positrones/métodos , Tomografía Computarizada por Rayos X/métodos , Adulto , Anciano , Anciano de 80 o más Años , Reacciones Falso Positivas , Femenino , Humanos , Metástasis Linfática , Imagen por Resonancia Magnética/métodos , Masculino , Persona de Mediana Edad , Metástasis de la NeoplasiaRESUMEN
BACKGROUND: Positron emission tomography (PET)/computed tomography (CT) is a new imaging modality that provides exact coregistration of anatomic and metabolic data. We have investigated to what degree this new technique might affect the interpretation of PET images in a nonselected group of consecutive cancer patients, reflecting routine condition in a busy cancer center. METHODS: Whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG)-PET and PET/CT fusion image sets were compared in 100 consecutive, nonselected patients: 21 with head and neck cancer, 39 with chest malignancies, and 40 with malignancies of the abdomen and pelvis. All studies were performed for primary staging or evaluation of therapy and were interpreted by two nuclear medicine physicians also trained in radiology. Areas of abnormal FDG uptake were identified on PET and graded as likely benign, equivocal, or likely malignant. Positron emission tomography/computed tomography fusion images were then made available, and the initial findings were amended if necessary. RESULTS: One hundred sixty-six areas with abnormal FDG uptake were identified. Based on PET alone, 51 sites were considered equivocal for malignancy. With PET/CT, the number of equivocal lesions decreased to 24. This difference is more marked in the head and neck as well as the abdomen and pelvis. When the equivocal sites were included in the analysis and grouped with the malignant sites, positive predictive value (PPV) of PET/CT was 89% compared with 75% for PET (p = 0.04). CONCLUSION: Combined PET/CT results in increased reader confidence and 53% fewer equivocal readings, as well as improved PPV compared with PET alone.
Asunto(s)
Fluorodesoxiglucosa F18 , Neoplasias/diagnóstico por imagen , Tomografía de Emisión de Positrones , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/patología , Tomografía Computarizada por Rayos XRESUMEN
PET/CT is a new imaging technology that has already found a number of clinical applications in oncologic imaging. Widespread introduction into clinical practice started approximately 2.5 years ago. Consequently, the available data are largely preliminary. Nevertheless, it can already be stated that the synthesis of structural and metabolic information improves the accuracy of primary staging and the detection of recurrent disease and has the realistic potential to change patient management in 10 to 20% of cases. PET/CT fusion images can directly guide biopsies or surgical interventions. This article summarizes preliminary data of PET/CT studies and highlights potential clinical applications for PET/CT, with particular emphasis on lymphoma, melanoma and gastrointestinal tumors.
Asunto(s)
Fluorodesoxiglucosa F18 , Neoplasias Gastrointestinales/diagnóstico , Aumento de la Imagen/métodos , Linfoma/diagnóstico , Técnica de Sustracción , Tomografía Computarizada de Emisión/métodos , Tomografía Computarizada por Rayos X/métodos , Neoplasias Gastrointestinales/diagnóstico por imagen , Neoplasias Gastrointestinales/patología , Humanos , Interpretación de Imagen Asistida por Computador/métodos , Linfoma/diagnóstico por imagen , Linfoma/patología , Melanoma/diagnóstico , Melanoma/diagnóstico por imagen , Melanoma/patología , Recurrencia Local de Neoplasia/diagnóstico , Recurrencia Local de Neoplasia/diagnóstico por imagen , Recurrencia Local de Neoplasia/patología , Estadificación de Neoplasias/métodos , Manejo de Atención al Paciente/métodos , Radiofármacos , Integración de SistemasRESUMEN
UNLABELLED: The routine use of PET/CT fusion imaging in a large oncology practice has led to the realization that (18)F-FDG uptake into normal fat and muscle can be a common source of potentially misleading false-positive PET imaging in the neck, thorax, and abdomen. The goal of this study was to characterize this normal variant of (18)F-FDG uptake in terms of incidence and characteristic extent. METHODS: All body scans done on our PET/CT scanners in July and August 2002 were retrospectively reviewed. All cases in which increased (18)F-FDG uptake in the neck was not localized to lymph nodes or other obvious anatomic sites on the CT scans were included in this study. Sites of any unexplained (18)F-FDG uptake in the rest of the body were also recorded. RESULTS: A total of 863 PET scans (476 males, 387 females; age, 2-88 y; mean age, 57 y) were reviewed. The following distinctive patterns of nonpathologic (18)F-FDG activity were observed: (a) neck fat, 20 patients (2.3%); (b) paravertebral uptake, 12 patients (1.4%); (c) perinephric fat, 7 patients (0.8%); (d) mediastinal fat, 8 patients (0.9%); (e) normal musculature, 12 patients (1.4%). Patients showing paravertebral uptake, perinephric fat, and mediastinal fat were all associated with the neck fat pattern, singly or in combination. On the other hand, patients showing the normal musculature pattern did not show any of the other uptake. In this analysis, the incidence of (18)F-FDG uptake in sites other than the neck is restricted to the patient population with neck fat uptake and may be an underestimation of the true incidence. Neck fat is found predominantly in females, whereas normal musculature is usually seen in males (P < 0.01, Fisher exact test). Neck fat is also seen significantly more in the pediatric population (4/26 = 15%) than in the adult population (16/837 = 1.9%) (P < 0.01, Fisher exact test). CONCLUSION: Increased (18)F-FDG uptake is sometimes seen in individual muscles and in adipose tissue in the neck and shoulder region, axillae, mediastinum, and perinephric regions. There is also associated (18)F-FDG uptake in the intercostal spaces in the paravertebral regions. (18)F-FDG uptake in neck fat is more commonly seen in female patients and the pediatric population. The pattern of uptake as well as the age and sex distribution suggest that the (18)F-FDG in fat is in the brown adipose tissue. It is important to recognize this uptake pattern to avoid false interpretation of this benign normal variant as a malignant finding on (18)F-FDG PET scans.
Asunto(s)
Tejido Adiposo/metabolismo , Fluorodesoxiglucosa F18 , Músculos/metabolismo , Tomografía Computarizada de Emisión , Tejido Adiposo Pardo/metabolismo , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Reacciones Falso Positivas , Femenino , Humanos , Masculino , Persona de Mediana Edad , CuelloRESUMEN
UNLABELLED: The standardized uptake value (SUV) is the most commonly used parameter to quantify the intensity of radiotracer uptake in tumors. Previous studies suggested that measurements of (18)F-FDG accumulation in tissue might be affected by the image reconstruction method, but the clinical relevance of these findings has not been assessed. METHODS: Phantom studies were performed and clinical whole-body (18)F-FDG PET images of 85 cancer patients were analyzed. All images were reconstructed using either filtered backprojection (FBP) with measured attenuation correction (MAC) or iterative reconstruction (IR) with segmented attenuation correction (SAC). In a subset of 15 patients, images were reconstructed using all 4 combinations of IR+SAC, IR+MAC, FBP+SAC, and FBP+MAC. For phantom studies, a sphere containing (18)F-FDG was placed in a water-filled cylinder and the activity concentration of that sphere was measured in FBP and IR reconstructed images using all 4 combinations. Clinical studies were displayed simultaneously and identical regions of interest (ROIs, 50 pixels) were placed in liver, urinary bladder, and tumor tissue in both image sets. SUV max (maximal counts per pixel in ROI) and SUV avg (average counts per pixel) were measured. RESULTS: In phantom studies, measurements from FBP images underestimated the true activity concentration to a greater degree than those from IR images (20% vs. 5% underestimation). In patient studies, SUV derived from FBP images were consistently lower than those from IR images in both normal and tumor tissue: Tumor SUV max with IR+SAC was 9.6 +/- 4.5, with IR+MAC it was 7.7 +/- 3.5, with FBP+MAC it was 6.9 +/- 3.0, and with FBP+SAC it was 8.6 +/- 4.1 (all P < 0.01 vs. IR+SAC). Compared with IR+SAC, SUV from FBP+MAC images were 25%-30% lower. Similar discrepancies were noted for liver and bladder. Discrepancies between measurements became more apparent with increasing (18)F-FDG concentration in tissue. CONCLUSION: SUV measurements in whole-body PET studies are affected by the applied methods for both image reconstruction and attenuation correction. This should be considered when serial PET studies are done in cancer patients. Moreover, if SUV is used for tissue characterization, different cutoff values should be applied, depending on the chosen method for image reconstruction and attenuation correction.
Asunto(s)
Algoritmos , Fluorodesoxiglucosa F18 , Aumento de la Imagen/métodos , Interpretación de Imagen Asistida por Computador/métodos , Neoplasias/diagnóstico por imagen , Tomografía Computarizada de Emisión/métodos , Recuento Corporal Total/métodos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fantasmas de Imagen , Radiofármacos , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Tomografía Computarizada de Emisión/instrumentación , Recuento Corporal Total/instrumentaciónRESUMEN
UNLABELLED: Metastatic prostate cancer may respond initially to hormone suppression, with involution of tumor sites, but ultimate tumor progression is inevitable. Our aim was to detect the proportion of bone and soft-tissue lesions that represent metabolically active tumor sites in patients with progressive metastatic prostate cancer. METHODS: In a prospective study, we compared 18F-FDG and L-methyl-11C-methionine (11C-methionine) PET with conventional imaging modalities (CIM), which included the combination of 99mTc-methylene diphosphonate scintigraphy, CT, or MRI. Twelve patients with prostate cancer, increasing levels of prostate-specific antigen (PSA), and at least 1 site (index lesion) with new or increasing disease on CIM were studied. The total numbers of soft-tissue and bone-tissue lesions, in a site-by-site comparison, were calculated for all imaging modalities. RESULTS: The sensitivities of 18F-FDG PET and 11C-methionine PET were 48% (167/348 lesions) and 72.1% (251/348 lesions), respectively, with CIM being used as the 100% reference (348/348). 11C-Methionine PET identified significantly more lesions than 18F-FDG PET (P < 0.01). All 12 patients with progressive metastatic prostate cancer had at least 1 lesion site of active metabolism for 18F-FDG or 11C-methionine, which could be used as an index lesion to monitor the metabolic response to therapy. A significant proportion of lesions (26%) had no detectable metabolism of 18F-FDG or 11C-methionine. Although technical factors cannot be totally excluded, we believe that metabolically inactive sites may be necrotic or dormant. More than 95% (251/258) of metabolically active sites (72% of the total number of lesions detected by CIM) metabolize 11C-methionine. 18F-FDG uptake is more variable, with 65% of metabolically active sites (48% of the total number of lesions detected by CIM). CONCLUSION: These findings reflect the different biologic characteristics of the lesions in a heterogeneous tumor such as prostate cancer and suggest that a time-dependent metabolic cascade may occur in advanced prostate cancer, with initial uptake of 11C-methionine in dormant sites followed by increased uptake of 18F-FDG during progression of disease.
Asunto(s)
Adenocarcinoma/diagnóstico por imagen , Adenocarcinoma/secundario , Neoplasias Óseas/diagnóstico por imagen , Neoplasias Óseas/secundario , Radioisótopos de Carbono , Fluorodesoxiglucosa F18 , Metionina , Neoplasias de la Próstata/patología , Radiofármacos , Neoplasias de los Tejidos Blandos/diagnóstico por imagen , Neoplasias de los Tejidos Blandos/secundario , Tomografía Computarizada de Emisión , Adenocarcinoma/diagnóstico , Anciano , Neoplasias Óseas/diagnóstico , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Sensibilidad y Especificidad , Neoplasias de los Tejidos Blandos/diagnóstico , Tomografía Computarizada por Rayos XRESUMEN
Most positron emission tomography (PET) imaging studies in head and neck cancer are performed using the radiotracer 18-fluorodeoxyglucose ((18)FDG). PET with FDG has become a standard clinical imaging modality in patients with head and neck cancer. It contributes valuable information in localizing a primary tumor in patients with neck nodal metastases from an unknown primary, in the staging of primary head and neck cancer, and in the detection of recurrent disease. In addition, FDG-PET provides independent prognostic information in patients with newly diagnosed and recurrent head and neck cancer. PET/CT improves lesion localization and accuracy of FDG-PET and is strongly recommended in patients with head and neck cancer. After thyroidectomy, FDG-PET has proven useful in patients with clinical or serological evidence of recurrent or metastatic thyroid carcinoma but negative whole body iodine scan. PET shows metastatic disease in up to 90% of these patients, thereby providing a rational basis for further studies and therapy. In patients with medullary thyroid cancer with elevated calcitonin levels following thyroidectomy, FDG-PET has a sensitivity of 70-75% for localizing metastatic disease. Occasionally incidental intense FDG uptake is observed in the thyroid gland on whole body PET studies performed for other indications. Although diffuse FDG uptake usually indicates thyroiditis, focal uptake has been related to thyroid cancer in 25-50% of cases and should therefore be evaluated further if a proven malignancy would cause a change in patient management.
Asunto(s)
Fluorodesoxiglucosa F18 , Neoplasias de Cabeza y Cuello/diagnóstico por imagen , Neoplasias de Cabeza y Cuello/secundario , Recurrencia Local de Neoplasia/diagnóstico por imagen , Recurrencia Local de Neoplasia/secundario , Neoplasias Primarias Desconocidas/diagnóstico por imagen , Tomografía Computarizada de Emisión/métodos , Neoplasias de Cabeza y Cuello/terapia , Humanos , Interpretación de Imagen Asistida por Computador/métodos , Recurrencia Local de Neoplasia/terapia , Neoplasias Primarias Desconocidas/terapia , Pronóstico , Radiografía , Radiofármacos , Técnica de Sustracción , Neoplasias de la Tiroides/diagnóstico por imagen , Neoplasias de la Tiroides/secundario , Neoplasias de la Tiroides/terapiaRESUMEN
The new combined positron emission (PET)/computed tomographic (CT) scanners have many advantages over PET scanners alone. However, physicians must be aware of the potential artefacts observed in PET/CT scanners. A body PET/CT was performed on an 81-year-old man with colorectal cancer. The CT-based, attenuation-corrected PET image showed a right lower lung lesion. However, there was no lung lesion on the transmission CT image. Nonattenuation-corrected PET, and rod source-based, attenuation-corrected PET images demonstrated focal uptake in the dome of the liver. Dedicated CT with intravenous contrast confirmed that the lesion was in the liver dome and not in the right lower lung. The liver lesion was misplaced to the right lower lung in the CT-based, attenuation-corrected PET image because of a respiratory artefact. To overcome this respiration artefact the authors suggest a routine review of the nonattenuation-corrected PET images, particularly when evaluating liver dome and lower lung lesions.
Asunto(s)
Artefactos , Neoplasias Hepáticas/diagnóstico por imagen , Hígado/diagnóstico por imagen , Pulmón/diagnóstico por imagen , Respiración , Tomografía Computarizada de Emisión , Anciano , Anciano de 80 o más Años , Fluorodesoxiglucosa F18 , Humanos , Procesamiento de Imagen Asistido por Computador , Masculino , Radiofármacos , Tomografía Computarizada por Rayos XAsunto(s)
Aumento de la Imagen/métodos , Interpretación de Imagen Asistida por Computador/métodos , Neoplasias/diagnóstico , Tomografía de Emisión de Positrones/métodos , Técnica de Sustracción , Tomografía Computarizada por Rayos X/métodos , Ensayos Clínicos como Asunto , Humanos , Hallazgos Incidentales , Variaciones Dependientes del Observador , Garantía de la Calidad de Atención de Salud/métodos , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
BACKGROUND: Histologic response to preoperative chemotherapy is a strong prognostic factor for osteosarcoma (OS). Thallium-201 (Tl-201) scintigraphic response to initial chemotherapy has previously been described as a predictor of histologic response. In the current study, the authors re-examined a series of patients studied using Tl-201 scintigraphy to determine the correlation between changes observed on Tl-201 scintigraphy and event-free survival (EFS). METHODS: A total of 22 patients with biopsy-proven OS of the extremity underwent Tl-201 imaging before and immediately after preoperative chemotherapy. The maximum pixel counts taken over the tumor divided by those taken of a background region yielded a tumor-to-background ratio (TBR). The percentage of change in the TBR before and after adjuvant chemotherapy, defined as the alteration ratio (AR), was correlated with EFS. RESULTS: The median AR was 85% (range, 28-100%). The 3-year EFS was 0.72 (95% confidence interval [95% CI], 0.48-0.86) and the 5-year EFS was 0.67 (95% CI, 0.43-0.86). There was no association between AR and EFS detected in this cohort (hazard ratio, 0.99; 95% CI, 0.95-1.02 [Somers rank correlation coefficient, 0.15]). CONCLUSIONS: Although Tl-201 scintigraphy was used as a tool for the assessment of response to chemotherapy in patients with OS, the AR did not appear to be predictive of EFS in this small group of patients. It is necessary to use the outcome variables of ultimate interest-EFS and overall survival- and not rely on surrogates for outcome to evaluate potential prognostic factors.
Asunto(s)
Neoplasias Óseas/diagnóstico por imagen , Osteosarcoma/diagnóstico por imagen , Radioisótopos de Talio , Adulto , Neoplasias Óseas/tratamiento farmacológico , Niño , Preescolar , Diagnóstico por Imagen , Supervivencia sin Enfermedad , Femenino , Humanos , Masculino , Osteosarcoma/tratamiento farmacológico , Pronóstico , CintigrafíaRESUMEN
OBJECTIVE: FDG PET is frequently used as part of the diagnostic workup in cancer patients. Visualization of radiotracer-avid foci suggests the presence of malignant disease. Unexplained focal FDG accumulation in the abdomen is sometimes noted, but the clinical significance of this finding is unknown. Therefore, we followed cases with unexplained focal abdominal FDG uptake found incidentally on whole-body scans to define the cause and clinical significance of this finding. CONCLUSION: Unexplained focal abdominal FDG uptake is an unusual finding with causes that include malignant and benign processes. Among the 14 cases with definitive diagnoses, seven were adenomas, which is a premalignant condition, and five (35.7%) were malignant. Therefore, although rare, unexplained focal abdominal FDG uptake should not be ignored and further diagnostic workup is warranted.
Asunto(s)
Abdomen/fisiopatología , Fluorodesoxiglucosa F18 , Neoplasias/diagnóstico por imagen , Radiofármacos , Tomografía Computarizada de Emisión , Anciano , Diagnóstico Diferencial , Femenino , Fluorodesoxiglucosa F18/farmacocinética , Humanos , Masculino , Persona de Mediana Edad , Radiofármacos/farmacocinéticaRESUMEN
PURPOSE: To compare diagnostic accuracy of attenuation-corrected positron emission tomography (PET) with fused PET and computed tomography (CT) in patients with head and neck cancer and to evaluate the effect of PET/CT findings on patient care. MATERIALS AND METHODS: Studies of 68 patients were reviewed by two physicians in consensus. Focal fluorodeoxyglucose (FDG) uptake in the head and neck on attenuation-corrected PET images was graded as benign, equivocal, or malignant. CT and PET/CT images were then reviewed, and initial findings were amended if necessary. Comparison was performed on a lesion-by-lesion basis. Accuracy was evaluated on the basis of follow-up and histopathologic findings. Potential effects on patient care were assessed by a head and neck surgeon. PET and PET/CT accuracy was compared with a McNemar test adjusted for clustering. RESULTS: A total of 157 foci with abnormal FDG uptake were noted, two of which were seen only on PET/CT images. PET/CT images were essential in determining the exact anatomic location for 100 lesions (74% better localization in regions previously treated surgically or with irradiation vs 58% in untreated areas; P =.06). On the basis of PET findings alone, 45 lesions were considered benign; 39, equivocal; and 71, malignant. With PET/CT, the fraction of equivocal lesions decreased by 53%, from 39 of 155 to 18 of 157 (P <.01). PET/CT had a higher accuracy of depicting cancer than did PET (96% vs 90%, P =.03). Six proved malignancies were missed with PET, but only one was missed with PET/CT. PET/CT findings altered the care for 12 (18%) of 68 patients. CONCLUSION: PET/CT is more accurate than PET alone in the detection and anatomic localization of head and neck cancer and has the clear potential to affect patient care.
Asunto(s)
Carcinoma de Células Escamosas/diagnóstico , Neoplasias de Cabeza y Cuello/diagnóstico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Células Escamosas/clasificación , Carcinoma de Células Escamosas/terapia , Reacciones Falso Positivas , Femenino , Fluorodesoxiglucosa F18/metabolismo , Estudios de Seguimiento , Neoplasias de Cabeza y Cuello/clasificación , Neoplasias de Cabeza y Cuello/terapia , Humanos , Interpretación de Imagen Asistida por Computador , Ganglios Linfáticos/diagnóstico por imagen , Ganglios Linfáticos/metabolismo , Masculino , Persona de Mediana Edad , Músculo Esquelético/diagnóstico por imagen , Músculo Esquelético/metabolismo , Atención al Paciente , Radiofármacos/metabolismo , Estudios Retrospectivos , Sensibilidad y Especificidad , Tomografía Computarizada de Emisión , Tomografía Computarizada por Rayos XRESUMEN
This review discusses the technical background of combined PET and CT and considers the clinical applications of PET/CT imaging. Questions addressed include: Is PET/CT superior to PET imaging alone? If so, in which patient populations and in what respect? Can PET/CT imaging affect patient management? Can PET/CT be practiced economically? While much work remains to be done, the available data clearly suggest that PET/CT decreases imaging time per patient and, even for the experienced reader, significantly reduces the number of equivocal PET interpretations. PET/CT also has the ability to improve accuracy of PET image interpretation and to affect clinical decision making, thereby improving patient management. The nuclear medicine community should approach this new technology with an open mind and focus on its clinical usefulness. The decision regarding whether PET/CT should be part of the equipment in a given nuclear medicine or radiology practice largely depends on the specific patient population. It is concluded that present skepticism concerning combined PET/CT will subside once critics of this new modality have had the opportunity to clearly see on images its many advantages compared with either PET alone or conventional image fusion approaches.